A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C-Reference-Cited by-同舟云学术

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C

Published:2005-05 Issue:3 Volume:12 Page:292-299
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Mangia A.,Ricci G. L.,Persico M.,Minerva N.,Carretta V.,Bacca D.,Cela M.,Piattelli M.,Annese M.,Maio G.,Conte D.,Guadagnino V.,Pazienza V.,Festi D.,Spirito F.,Andriulli A.

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2893.2005.00591.x/fullpdf

Reference23 articles.

1. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

3. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and Incidence of Depression during Interferon-Based Antiviral Therapy in Chronic Hepatitis C Patients in the Republic of Korea;Gut and Liver;2017-05-15

2. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C;Cochrane Database of Systematic Reviews;2014-02-28

3. The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives;Chemical Reviews;2013-02-25

4. Prevention of Cancers Due to Infection;Epidemiologic Studies in Cancer Prevention and Screening;2012-10-11

5. Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients;International Journal of Infectious Diseases;2012-10